Financial reports
10-Q
2024 Q2
Quarterly report
1 Aug 24
ARS
2023 FY
Annual report to shareholders
24 Jul 24
10-Q
2024 Q1
Quarterly report
25 Apr 24
10-K
2023 FY
Annual report
1 Feb 24
ARS
2022 FY
Annual report to shareholders
19 Dec 23
10-Q
2023 Q3
Quarterly report
18 Oct 23
10-Q
2023 Q1
Quarterly report
21 Jul 23
10-Q
2023 Q1
Quarterly report
24 Apr 23
10-K
2022 FY
Annual report
24 Feb 23
10-Q
2022 Q3
Quarterly report
28 Oct 22
Current reports
8-K
Departure of Directors or Certain Officers
4 Oct 24
8-K
Oruka Therapeutics Announces $200 Million Private Placement
13 Sep 24
8-K
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5 Sep 24
8-K
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
26 Aug 24
8-K
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
23 Aug 24
8-K
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
16 Aug 24
8-K
Entry into a Material Definitive Agreement
15 Aug 24
8-K
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
1 Aug 24
8-K
Entry into a Material Definitive Agreement
9 Jul 24
8-K
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
25 Apr 24
Registration and prospectus
425
Business combination disclosure
26 Aug 24
425
Business combination disclosure
16 Aug 24
425
Business combination disclosure
15 Aug 24
425
Business combination disclosure
9 Aug 24
425
Business combination disclosure
1 Aug 24
424B3
Prospectus supplement
1 Aug 24
425
Business combination disclosure
9 Jul 24
Proxies
DEF 14A
Definitive proxy
18 Oct 24
PRE 14A
Preliminary proxy
7 Oct 24
DEFA14A
Additional proxy soliciting materials
19 Dec 23
DEF 14A
Definitive proxy
19 Dec 23
DEFA14A
Additional proxy soliciting materials
3 Nov 22
DEF 14A
Definitive proxy
3 Nov 22
DEFA14A
Additional proxy soliciting materials
28 Jun 21
DEFA14A
Additional proxy soliciting materials
21 Apr 21
DEF 14A
Definitive proxy
21 Apr 21
DEFA14A
Additional proxy soliciting materials
9 Dec 20
Other
EFFECT
Notice of effectiveness
25 Jul 24
EFFECT
Notice of effectiveness
31 Mar 21
CORRESP
Correspondence with SEC
26 Mar 21
UPLOAD
Letter from SEC
26 Mar 21
EFFECT
Notice of effectiveness
21 May 20
CORRESP
Correspondence with SEC
18 May 20
UPLOAD
Letter from SEC
14 May 20
CT ORDER
Confidential treatment order
17 May 19
CT ORDER
Confidential treatment order
10 May 18
CT ORDER
Confidential treatment order
13 Dec 17
Ownership
SC 13G
FMR LLC
7 Oct 24
SC 13D/A
Fairmount Funds Management LLC
13 Sep 24
4
Peter Evan Harwin
13 Sep 24
SC 13D
Fairmount Funds Management LLC
6 Sep 24
3
Peter Evan Harwin
6 Sep 24
3
Cameron Turtle
6 Sep 24
3
Samarth Kulkarni
6 Sep 24
3
Carl Dambkowski
6 Sep 24
3
KRISTINE M BALL
6 Sep 24
3
Paul T Quinlan
6 Sep 24